GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pheton Holdings Ltd (NAS:PTHL) » Definitions » Notes Receivable

PTHL (Pheton Holdings) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pheton Holdings Notes Receivable?

Pheton Holdings's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Pheton Holdings Notes Receivable Historical Data

The historical data trend for Pheton Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pheton Holdings Notes Receivable Chart

Pheton Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Pheton Holdings Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial - - - - -

Pheton Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Pheton Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Pheton Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pheton Holdings Business Description

Traded in Other Exchanges
N/A
Address
Hong Jun Ying South Road, Room 306, NET Building, Chaoyang District, Beijing, CHN, 100101
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

Pheton Holdings Headlines